Research Papers:

NOD2 maybe a biomarker for the survival of kidney cancer patients

Deguo Xu, Shuisheng Zhang, Shenfeng Zhang, Hongmei Liu, Paiyun Li, Lili Yu, Heli Shang, Yong Hou and Yuan Tian _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:101489-101499. https://doi.org/10.18632/oncotarget.21547

Metrics: PDF 1554 views  |   HTML 2507 views  |   ?  


Deguo Xu1,*, Shuisheng Zhang2,*, Shenfeng Zhang3,*, Hongmei Liu1,*, Paiyun Li4,*, Lili Yu1, Heli Shang1, Yong Hou1 and Yuan Tian1

1Department of Radiation Oncology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong Province 250014, P.R. China

2Department of Abdominal Surgical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China

3Department of Oncology, Zaozhuang Municipal Hospital of Shandong Province, Shizhong District, Zaozhuang, Shandong Province 277101, P.R. China

4Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Aetiology, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China

*These authors contributed equally to this work

Correspondence to:

Yuan Tian, email: [email protected]

Keywords: NOD2 gene, kidney cancer, survival, prognosis

Received: August 02, 2017     Accepted: September 20, 2017     Published: October 06, 2017


Background: Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) may play an important role in the outcome of kidney cancer patients. To explore the relationship between NOD2 and the prognosis of kidney cancer patients, a databank-based reanalysis was conducted.

Materials and Methods: Data related to kidney cancer patients at least with survival information, was obtained mainly from The Cancer Genome Atlas (TCGA). Some clinical data, not available online, was collected by personal email to the author. Then, we reanalyzed all the data in order to make a conclusion about the relationship between NOD2 gene and the prognosis of kidney cancer patients.

Results: A total of 1953 samples with NOD2 information from four databanks of The Cancer Genome Atlas (TCGA) were enrolled in this study. The results of KIPAN showed the Kaplan-Meier curve for risk groups, concordance index, and p-value of the log-rank testing equality of survival curves ( Concordance Index = 56.57, Log−Rank Equal Curves p=0.0009006, R^2 = 0.036/0.953, Risk Groups Hazard Ratio = 1.61 (conf. int. 1.21 ~ 2.13), p = 0.001005) , while a box plot across risk groups, including the p-value testing for difference using t-test (or f-test for more than two groups) was shown. There was a statistical significance for the p value of the result (p < 0.01 ). The similar results could be seen in KIRC and the fourth data (including 468 samples).

Conclusions: The status of NOD2 gene maybe a biomarker for the survival of kidney cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21547